Production & Sales

Aligos and Xiamen Amoytop sign deal for HBV therapy

Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.

Idorsia and Pharmalink sign agreement to distribute Quviviq

Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in Kuwait, Oman, Qatar, Bahrain, and the United Arab Emirates (UAE).

Asahi Kasei to acquire Aicuris Anti-infective Cures for $920.7m

Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m).

Quotient and Ipsen extend partnership for ultra-rare disease therapy

Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP).

Citius Oncology and Uniphar sign European distribution deal for Lymphir

Citius Pharmaceuticals’ subsidiary Citius Oncology has signed an exclusive distribution agreement with Uniphar to enable access to Lymphir (denileukin diftitox-cxdl) in selected European countries.

BMS reports flat revenue growth for full-year 2025

Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.

IQVIA and Boehringer Ingelheim collaborate on therapeutic data transformation

IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas. 

Johnson & Johnson reports 9.1% increase in sales for Q4 2025

Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn.

AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.